Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vascular Solutions Not-Guilty Verdict Another Challenge To FDA Off-Label Oversight

This article was originally published in The Gray Sheet

Executive Summary

The case against the venous device manufacturer turned on the rights of manufacturers to use truthful off-label speech to promote their products. It joins a growing body of cases in which courts have sanctioned broader off-label speech than has traditionally been allowed by FDA.


Related Content

Pharma Pricing, Non-Profit Ties Get Increasing Scrutiny From Prosecutors
Former Acclarent Execs Convicted Of Misdemeanors In Off-Label Case
Case-By-Case Changes To Off-label Promotion
FDA Focusing Enforcement Efforts on GMP Compliance As Off-Label Prosecutions Wane
Vascular Solutions Case May Point Way Forward For Off-Label Marketing
Vascular Solutions Case (Partially) Points Way Forward For Off-Label Marketing
In Case You Missed It: Top 10 Gray Sheet Stories In March
Vascular Solutions Alleges Misconduct In Off-Label Case
Vascular Solutions Fights Criminal Misbranding Charges In Vari-Lase Case


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts